1996JAMARequires access

Intranasal lidocaine for treatment of migraine

Merle L. Diamond

Open publisher page 0 citations

Abstract

To the Editor. —The suggested use of intranasal lidocaine 4% for the acute treatment of migraine is an interesting proposition that may offer hope as a useful analgesic option. However, the article by Dr Maizels and colleagues 1 did not clearly address the use and dosage of this medication. In high doses, lidocaine can cause significant morbidity, resulting in confusion, agitation, seizures, and cardiac dysrhythmias. Intranasal lidocaine can be absorbed systemically and could be potentially toxic if the patient uses the agent excessively. The risk for toxicity due to frequent use is underscored by the brief duration of action of lidocaine and the high recurrence rate of acute migraine. Also, the authors note the high relapse rate for headache early after treatment. Further studies are essential to determine safe and judicious prescription labeling of lidocaine for treatment of acute migraine.

About this research paper

What this paper is about

To the Editor. —The suggested use of intranasal lidocaine 4% for the acute treatment of migraine is an interesting proposition that may offer hope as a useful analgesic option. However, the article by Dr Maizels and colleagues 1 did not clearly address the use and dosage of this medication. In high doses, lidocaine can cause significant morbidity, resulting in confusion, agitation, seizures, and cardiac dysrhythmias. Intranasal lidocaine can be absorbed systemically and could be potentially toxic if the patient uses the agent excessively. The risk for toxicity due to frequent use is underscored by the brief duration of action of lidocaine and the high recurrence rate of acute migraine. Also, the authors note the high relapse rate for headache early after treatment. Further studies are essential to determine safe and judicious prescription labeling of lidocaine for treatment of acute migraine.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

To the Editor. —The suggested use of intranasal lidocaine 4% for the acute treatment of migraine is an interesting proposition that may offer hope as a useful analgesic option. However, the article by Dr Maizels and colleagues 1 did not clearly address the use and dosage of this medication. In high doses, lidocaine can cause significant morbidity, resulting in confusion, agitation, seizures, and cardiac dysrhythmias. Intranasal lidocaine can be absorbed systemically and could be potentially toxic if the patient uses the agent excessively. The risk for toxicity due to frequent use is underscored by the brief duration of action of lidocaine and the high recurrence rate of acute migraine. Also, the authors note the high relapse rate for headache early after treatment. Further studies are essential to determine safe and judicious prescription labeling of lidocaine for treatment of acute migraine.

Key concepts: Medicine, Lidocaine, Migraine, Nasal administration, Migraine Disorders, Anesthesia, Pharmacology

Related papers

Back to paper searchBrowse research topicsOriginal source
Intranasal lidocaine for treatment of migraine — Research Paper | ScholarLens